DexCom (DXCM) shares rallied 5.6% in the last trading session to close at $80.04. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 1.8% gain over the past four weeks.The sharp upsurge in Dexcom's shares can be attributed to the Novo Nordisk's announcement that its next-generation weight-loss drug, CagriSema, did not meet the high expectations in a key study, achieving a 22.7% weight loss instead of the anticip ...

Shares of the medical-device maker DexCom (DXCM 5.57%) are down by 37% this year. The diabetes-focused healthcare company disappointed investors with its second-quarter results, leading to a massive drop in its stock price overnight. Though the issues DexCom has faced this year can mainly be classified as "short-term headwinds" -- including rebate-related issues -- there are more serious problems for the company's long-term prospects.On the other hand, DexCom has attractive opportunities that could allow it ...

DexCom Inc. (DXCM) recently announced the launch of a proprietary Generative AI (GenAI) platform, making Dexcom the first Continuous Glucose Monitoring (CGM) manufacturer to integrate GenAI into glucose biosensing technology.In addition to offering practical insights to support the improvement of metabolic health, the new Dexcom GenAI platform is likely to examine trends in individual health data to uncover a clear correlation between lifestyle decisions and blood glucose levels. Dexcom leveraged Google Clo ...

The Dexcom logo is seen on a smartphone screen and in the background.Dexcom on Tuesday announced an artificial intelligence feature for its Stelo continuous glucose monitor that gives users a personalized look into how meals, sleep and activity impact their glucose levels. It's the first iteration of a new generative AI platform that the company has been building with Google Cloud. Stelo is an over-the-counter CGM that pokes through the skin to measure real-time blood sugar levels. The sensor launched in Au ...

DexCom, Inc. (DXCM) is well-poised for growth in the coming quarters, backed by its strong product portfolio. A better-than-expected third-quarter 2024 performance and a series of favorable coverage decisions are expected to contribute further. However, risks related to stiff competition persist.This Zacks Rank #3 (Hold) company’s shares have lost 36.5% year to date against the industry’s 6.7% growth. The S&P 500 Index has soared 28.6% in the same time frame.DXCM, a renowned medical device company and provi ...

Medical device specialist DexCom (DXCM -0.14%) is going through a rough patch. The company's shares are down sharply year to date due to unimpressive financial results -- and some of the headwinds it has encountered are, no doubt, concerning. The company's slower-than-expected growth in international markets in the second quarter comes to mind.However, there remain excellent reasons to be bullish on DexCom's long-term prospects. Let's consider three of them.1. The power of CGM systemsDexCom is a leader in t ...

Although excellent medical care is always in high demand, the healthcare sector continuously evolves. Companies aren't automatically worth investing in just because they provide essential medical services. Only those that can keep up with the changing nature of the industry can hope to deliver excellent returns over the long run.There are many such stocks on the market. Let's consider two that specialize in developing medical devices: DexCom (DXCM 0.20%) and Intuitive Surgical (ISRG -0.66%). These healthcar ...

It's not always easy to be a long-term investor, particularly when contending with the natural cyclicality that the stock market presents if you buy and hold through bull as well as bear markets.Investing consistently during all types of market environments is key. So is maintaining your positions in quality companies unless and until your investment thesis regarding them no longer applies, or you feel that they have exhausted their value proposition for your portfolio.If you're looking for unstoppable grow ...

DexCom (DXCM) , a leader in glucose biosensing systems, has announced a strategic partnership with OURA, the developer of a leading smart ring technology. The collaboration is aimed at revolutionizing metabolic health management by integrating DexCom's glucose biosensor data with the biometric insights provided by the Oura Ring. The partnership will enable two-way data flow between DexCom glucose biosensors and apps and Oura Ring and the Oura App, and co-marketing efforts will help OURA and Dexcom reach mil ...

This medical device company is down but not out.Is the sky falling for DexCom (DXCM 0.89%)? Shares of the medical device specialist dropped off a cliff following its second-quarter earnings report. Unfortunately, the diabetes-focused company failed to impress investors yet again with its most recent quarterly update.At about $69 per share, DexCom's stock isn't that far off its 52-week low of $62.34 and is miles away from its 52-week high of $142. However, there remain good reasons to invest in the company.D ...